The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450

Drug Metabolism and Disposition

Volumn 30, Issue 9, 2002, Pages 957-961

  Ring, Barbara J ^a   Gillespie, Jennifer S ^a   Binkley, Shelly N ^a   Campanale, Kristina M ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21:12,17 DIMETHENODIBENZO[E,K]PYRROLO[3,4 H][1,4,13]OXADIAZACYCLOHEXADECENE 18,20(19H) DIONE; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; KETOCONAZOLE; N NOR 9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21:12,17 DIMETHENODIBENZO[E,K]PYRROLO[3,4 H][1,4,13]OXADIAZACYCLOHEXADECENE 18,20(19H) DIONE; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; QUINIDINE; RUBOXISTAURIN; UNCLASSIFIED DRUG; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450 1A2; CYTOCHROME P450 3A; ENZYME INHIBITOR; INDOLE DERIVATIVE; ISOENZYME; MALEIMIDE DERIVATIVE; N DEMETHYLASE; PROTEIN KINASE C; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BIOTRANSFORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KINETICS; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG ANTAGONISM; IN VITRO STUDY; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMAN; IN VITRO; INDOLES; ISOENZYMES; MALEIMIDES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN KINASE C; CYTOCHROME P-450 CYP3A; HUMANS;

EID: 0036707614     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.9.957     Document Type: Article

References (20)

1. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures
2. A population approach to enzyme characterization and identification: Application to phenacetin O-deethylation
3. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose
4. Salt from selection and characterization of LY333531 mesylate monohydrate
5. Preferential elevation of protein kinase C isoform β2 and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
6. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor
7. (S)-13[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ
8. CYP1A
9. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
10. CYP2C
11. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A
12. Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine
13. Industrial viewpoint: Application of in vitro drug metabolism in various phases of drug development
14. Correlation of diaeylglycerol level and protein kinase C activity in rat retina to retinal circulation
15. Interindividual variations in human liver cytochromes P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
16. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism
17. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes
18. CYP3A
19. CYP2D6